Featured News

The Celiac Disease Foundation is matching donations, dollar for dollar, up to $25,000. Together we can protect those with celiac disease in crisis. 

Researchers found that children initially diagnosed with potential celiac disease had a high risk of developing celiac disease.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

The findings of the Research Opportunities in Celiac Disease Consensus Workshop, sponsored by the CDF, were published as a Research Roadmap for NIH.

On August 24, Rep. Betty McCollum launched the bipartisan Celiac Disease Caucus. We look forward to continuing to work with Rep. McCollum and the Caucus to support innovative research and advance legislation that will ease the suffering of celiac patients.

Please take one minute to email your Members of Congress to make it easier and safer for those with celiac disease to purchase food items by requiring labels to list the presence of barley and rye, in addition to wheat.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.